Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $1.17, $0.89 better than the analyst estimate of $0.28. Revenue for the quarter came in at $49.9 million versus the consensus estimate of $47.02 million.

2020 Expense Guidance:

• R&D expense in 2020, on a non-GAAP basis, is expected to be $40-$44 million, as compared to $31 million in 2019.
• SG&A spend in 2020, on a non-GAAP basis, is expected to be $61-$64 million, as compared to $56 million in 2019.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.